Literature DB >> 31090648

Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors.

Meghan E Sise1, Ian A Strohbehn2, Emily Bethea2, Jenna L Gustafson2, Raymond T Chung2.   

Abstract

PURPOSE OF REVIEW: Owing to long waitlist times and high waitlist morbidity and mortality, strategies to increase utilization of hepatitis C viremic-deceased donor organs are under investigation in kidney, liver, heart, and lung transplantation. RECENT
FINDINGS: Direct-acting antiviral medications for hepatitis C virus infection have high cure rates and are well tolerated. Small, single-center trials in kidney and heart transplant recipients have demonstrated that with early posttransplant direct-acting antiviral therapy, 100% of uninfected recipients of hepatitis C viremic organs have been cured of infection after transplantation.
SUMMARY: In this manuscript, we review the risks and rewards of utilizing hepatitis C viremic organs for transplantation.

Entities:  

Mesh:

Year:  2019        PMID: 31090648      PMCID: PMC7093034          DOI: 10.1097/MOT.0000000000000651

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  68 in total

Review 1.  Should organs from hepatitis C-positive donors be used in hepatitis C-negative recipients for liver transplantation?

Authors:  Nazia Selzner; Marina Berenguer
Journal:  Liver Transpl       Date:  2018-06       Impact factor: 5.799

2.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Michael Manns; Didier Samuel; Edward J Gane; David Mutimer; Geoff McCaughan; Maria Buti; Martín Prieto; José Luis Calleja; Markus Peck-Radosavljevic; Beat Müllhaupt; Kosh Agarwal; Peter Angus; Eric M Yoshida; Massimo Colombo; Mario Rizzetto; Hadas Dvory-Sobol; Jill Denning; Sarah Arterburn; Phillip S Pang; Diana Brainard; John G McHutchison; Jean-François Dufour; Hans Van Vlierberghe; Bart van Hoek; Xavier Forns
Journal:  Lancet Infect Dis       Date:  2016-02-18       Impact factor: 25.071

Review 3.  Side effects of alpha interferon in chronic hepatitis C.

Authors:  G Dusheiko
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

4.  Transplanting Hepatitis C-Positive Kidneys.

Authors:  Peter P Reese; Peter L Abt; Emily A Blumberg; David S Goldberg
Journal:  N Engl J Med       Date:  2015-07-23       Impact factor: 91.245

5.  Outcome of de novo hepatitis C virus infection in heart transplant recipients.

Authors:  J P Ong; D S Barnes; Z M Younossi; T Gramlich; B Yen-Lieberman; M Goormastic; C Sheffield; K Hoercher; R Starling; J Young; N Smedira; P McCarthy
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

6.  Use of Hepatitis C-Positive Donor Livers in Liver Transplantation.

Authors:  Daniel Bushyhead; David Goldberg
Journal:  Curr Hepatol Rep       Date:  2017-01-26

7.  Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list.

Authors:  Roy D Bloom; Gabriel Sayer; Kosunarty Fa; Serban Constantinescu; Peter Abt; K Rajender Reddy
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

8.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Authors:  Michael Charlton; Gregory T Everson; Steven L Flamm; Princy Kumar; Charles Landis; Robert S Brown; Michael W Fried; Norah A Terrault; Jacqueline G O'Leary; Hugo E Vargas; Alexander Kuo; Eugene Schiff; Mark S Sulkowski; Richard Gilroy; Kymberly D Watt; Kimberly Brown; Paul Kwo; Surakit Pungpapong; Kevin M Korenblat; Andrew J Muir; Lewis Teperman; Robert J Fontana; Jill Denning; Sarah Arterburn; Hadas Dvory-Sobol; Theo Brandt-Sarif; Phillip S Pang; John G McHutchison; K Rajender Reddy; Nezam Afdhal
Journal:  Gastroenterology       Date:  2015-05-15       Impact factor: 22.682

9.  Successful Treatment of Chronic Hepatitis C Infection With Direct-Acting Antivirals in a Heart Transplant Recipient: A Case Report.

Authors:  S Trakroo; K Qureshi
Journal:  Transplant Proc       Date:  2015-09       Impact factor: 1.066

10.  Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.

Authors:  Nancy Reau; Paul Y Kwo; Susan Rhee; Robert S Brown; Kosh Agarwal; Peter Angus; Edward Gane; Jia-Horng Kao; Parvez S Mantry; David Mutimer; K Rajender Reddy; Tram T Tran; Yiran B Hu; Abhishek Gulati; Preethi Krishnan; Emily O Dumas; Ariel Porcalla; Nancy S Shulman; Wei Liu; Suvajit Samanta; Roger Trinh; Xavier Forns
Journal:  Hepatology       Date:  2018-07-25       Impact factor: 17.425

View more
  1 in total

Review 1.  Transplantation of Organs from Hepatitis C Virus-Positive Donors under Direct-Acting Antiviral Regimens.

Authors:  Muhammad Nauman Zahid
Journal:  J Clin Med       Date:  2022-01-31       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.